Wang Yue, Li Ling-zhi, Ye Lu, Niu Xiu-long, Liu Xin, Zhu Ya-qin, Sun Wei-jia, Liang Yan-jun
Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard, Tianjin 300162, China.
Zhonghua Fu Chan Ke Za Zhi. 2010 Sep;45(9):691-8.
To study the mechanism of chemotherapy resistance caused by interleukin-6 (IL-6) in ovarian cancer cells and its related signal pathways.
Ovarian cancer cell lines A2780 (IL-6 receptor positive, while non-IL-6-expressing and cisplatin/paclitaxel-responsive) and SKOV3 cell lines (overexpressing of IL-6 receptor and IL-6 and cisplatin/paclitaxel-resistant) were suitable models for this study. The effect of exogenous (a short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) in A2780 cells or deleting of endogenous IL-6 expression in SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) on the sensitivity to cisplatin and paclitaxel was investigated. Meanwhile, the mechanism of chemotherapy resistance caused by IL-6 in ovarian cancer cells and its related signal pathways were also analyzed.
We found that both exogenous and endogenous IL-6 induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells (the resistance multiple to cisplatin and paclitaxel was: exogenous, 6.25 and 7.31; endogenous, 7.13-8.34 and 7.61-10.70), while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells promotes its sensitivity to anticancer drugs (the resistance multiple to cisplatin and paclitaxel was 0.15 and 0.10, 0.10 and 0.08). IL-6 significantly up-regulated the expression levels of mRNA and protein of drug resistance-associated genes, MDR1 and GST-π, and apoptosis-inhibiting genes, bcl-2, bcl-xL and XIAP in a dose-dependent manner in A2780 cells. In accordance with this finding, the mRNA and protein levels of MDR1 and GST-π enhanced in sense IL-6-transfected A2780 cells, and reduced in antisense IL-6-transfected SKOV3 cells compared with the corresponding parental and control vector-transfected cells, which had no difference. It was found that PD98059 [mitogen-activated protein kinase-extracellular signal-regulated kinase (MEK) inhibitor] and wortmannin [phosphatidylinositol 3-kinase (PI3K) inhibitor] significantly antagonized IL-6-induced phosphorylation of extracellular signal-regulated kinase (ERK) and protein kinase B (Akt), respectively, and both of them blocked IL-6-induced cisplatin and paclitaxel resistance and the inhibitory effects of PD98059 and wortmannin were dependent on its concentration.
These data suggest that IL-6-induced chemoresistance may be associated with increase of both drug resistance-associated genes (MDR1 and GST-π) and apoptosis-inhibiting genes (bcl-2, bcl-xL and XIAP), and activation of MEK/ERK and PI3K/Akt. Therefore, modulation of IL-6 expression or its related signaling pathway may be a promising strategy of treatment for drug-resistant ovarian cancer.
研究白细胞介素-6(IL-6)导致卵巢癌细胞化疗耐药的机制及其相关信号通路。
卵巢癌细胞系A2780(IL-6受体阳性,但不表达IL-6且对顺铂/紫杉醇敏感)和SKOV3细胞系(IL-6受体和IL-6过表达且对顺铂/紫杉醇耐药)是本研究的合适模型。研究外源性(用重组IL-6短期处理)和内源性IL-6(通过转染编码正义IL-6的质粒)对A2780细胞顺铂和紫杉醇敏感性的影响,以及在SKOV3细胞中缺失内源性IL-6表达(通过转染编码反义IL-6的质粒)对顺铂和紫杉醇敏感性的影响。同时,分析IL-6导致卵巢癌细胞化疗耐药的机制及其相关信号通路。
我们发现外源性和内源性IL-6均可诱导不表达IL-6的A2780细胞对顺铂和紫杉醇产生耐药(对顺铂和紫杉醇的耐药倍数分别为:外源性,6.25和7.31;内源性,7.13 - 8.34和7.61 - 10.70),而在IL-6过表达的SKOV3细胞中缺失内源性IL-6表达可提高其对抗癌药物的敏感性(对顺铂和紫杉醇的耐药倍数分别为0.15和0.10,0.10和0.08)。IL-6以剂量依赖的方式显著上调耐药相关基因MDR1和GST-π以及凋亡抑制基因bcl-2、bcl-xL和XIAP的mRNA和蛋白表达水平。与此发现一致,与相应的亲本细胞和对照载体转染细胞相比,正义IL-6转染的A2780细胞中MDR1和GST-π的mRNA和蛋白水平升高,反义IL-6转染的SKOV3细胞中MDR1和GST-π的mRNA和蛋白水平降低,而亲本细胞和对照载体转染细胞之间无差异。发现PD98059[丝裂原活化蛋白激酶-细胞外信号调节激酶(MEK)抑制剂]和渥曼青霉素[磷脂酰肌醇3激酶(PI3K)抑制剂]分别显著拮抗IL-6诱导的细胞外信号调节激酶(ERK)和蛋白激酶B(Akt)的磷酸化,并且它们都阻断了IL-6诱导的顺铂和紫杉醇耐药,且PD98059和渥曼青霉素的抑制作用取决于其浓度。
这些数据表明,IL-6诱导的化疗耐药可能与耐药相关基因(MDR1和GST-π)和凋亡抑制基因(bcl-2、bcl-xL和XIAP)的增加以及MEK/ERK和PI3K/Akt的激活有关。因此,调节IL-6表达或其相关信号通路可能是治疗耐药性卵巢癌的一种有前景的策略。